Sacubitril/valsartan - novel direction in heart failure treatment
- Authors: Taratukhin E.O.1
-
Affiliations:
- FSBEI HE Russian National Research Medical University n.a. Pirogov N.I
- Issue: No 1 (2018)
- Pages: 96-99
- Section: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/279263
- ID: 279263
Cite item
Open Access
Access granted
Abstract
The article is focused on the novel drug for congestive heart failure management - combination of valsartan and sacubitril, that has recently became available on pharmaceutical market, and has been included in the European Guidelines due to proven efficacy and safety. In the article, natriuretic system is described and the place of neprilysin in it. Mechanism of sacubitril is presented and rationale for its combination with valsartan. The data from the main clinical trials is given, as some recent references on the drug clinical usage.
Full Text
About the authors
Evgeny O. Taratukhin
FSBEI HE Russian National Research Medical University n.a. Pirogov N.I
Email: cardio030yandex.ru
MD, PhD, M.A., Associate Professor at the Department of Internal Medicine
References
- Becnel M.F., Ventura H.O., Krim SR. Changing our Approach to Stage D Heart Failure. Progress in cardiovascular diseases. 2017;60(2):205-214.
- Kristensen S.L., Jhund P.S., Mogensen U.M., Rorth R., Abraham W.T., Desai A., Dickstein K., Rouleau J.L., Zile M.R., Swedberg K., Packer M., Solomon S.D., K0ber L., McMurray J.J.V.; PARADIGM-HF and ATMOSPHERE Committees and Investigators. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circ. Heart Fail. 2017;10(10). pii: e004409.
- Singh J.S.S., Burrell L.M., Cherif M., Squire I.B., Clark A.L., Lang C.C. Sacubitril/valsartan: beyond natriuretic peptides. Heart. 2017;103(20):1 569-77.
- Obrezan A.G., Kulikov N.V. Neuro-humoral disbalance in chronic heart failure: classic and modern perspectives. Russ. J. Cardiol. 2017;149(9):83-92. (Russian: Обрезан А., Куликов Н. Нейрогуморальный дисбаланс при хронической сердечной недостаточности: классические и современные позиции. Российский кардиологический журнал. 2017;149(9):83-92).
- Niederkoer E., Kiernan U., O'Rear J. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ. Heart Fail. 2008(1):258-64.
- Sible A.M., Nawarskas J.J., Alajajian D., Anderson J.R. Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent. Cardiol. Rev. 2016;24(1):41-7.
- Packer M., McMurray J.J., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61.
- Bohm M., Young R., Jhund P.S., Solomon S.D., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Swedberg K., Zile M.R., Packer M., McMurray J.J.V. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/ valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017;38(15):1132-43.
- Barghash M.H., Desai A.S. First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice. Clinical pharmacology and therapeutics. 2017;102(2):265-8.
- Lewis E.F., Claggett B.L., McMurray J.J.V., Packer M., Lefkowitz M.P., Rouleau J.L., et al. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10(8).
- Mogensen U.M., Kober L., Kristensen S.L., Jhund P.S., Gong J., Lefkowitz M.P., et al. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. Am. Heart J. 2017;188:35-41.
- Pascual-Figal D.A. Neprilysin and Heart Failure: A "Sympathetic" Relationship? J. Am. Coll. Cardiol. 2017;70(17):2154-6.
- Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200.
Supplementary files
